^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CDH1 expression

i
Other names: CDH1, CD324, UVO, uvomorulin, Cadherin 1, type 1, E-cadherin
Entrez ID:
Related biomarkers:
19h
High core 1β1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma. (PubMed, J Cancer Res Clin Oncol)
Elevated C1GALT1 expression in LUAD is associated with an unfavorable prognosis and contributes to increased radioresistance potentially by affecting DNA repair, cell proliferation, cell cycle regulation, and epithelial-mesenchymal transition (EMT).
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CDH1 expression • VIM expression
21h
Prolactin-induced tyrosyl phosphorylation of PAK1 facilitates epithelial-mesenchymal transition. (PubMed, MicroPubl Biol)
pTyr-PAK1 also significantly increases PRL-dependent Slug activity leading to expression of vimentin, a hallmark of EMT. Thus, our current data on pTyr-PAK1 regulation of EMT bring insight into the role of PAK1 and PRL in human breast cancer.
Journal
|
JAK2 (Janus kinase 2) • CDH1 (Cadherin 1) • VIM (Vimentin) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
CDH1 expression • VIM expression
2d
Toxoplasma gondii suppresses proliferation and migration of breast cancer cells by regulating their transcriptome. (PubMed, Cancer Cell Int)
T. gondii transcriptionally regulates several signaling pathways by altering the hub genes such as BRCA1, MYC and IL-6, which can inhibit the breast tumor growth and migration, hinting at a potential therapeutic strategy.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • CD9 (CD9 Molecule) • IL17A (Interleukin 17A)
|
CDH1 expression
3d
A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. (PubMed, Sci Rep)
Notably, PDAC-X2 cells demonstrated resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil and oxaliplatin. In conclusion, PDAC-X2 presents an invaluable preclinical model. Its utility lies in facilitating the study of drug resistance mechanisms and the exploration of alternative therapeutic approaches aimed at enhancing the prognosis of this tumour type.
Preclinical • Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • KRT19 (Keratin 19) • CA 19-9 (Cancer antigen 19-9)
|
CDH1 expression
|
gemcitabine • paclitaxel • 5-fluorouracil • oxaliplatin
3d
Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis. (PubMed, J Control Release)
To prove our hypothesis, we have developed liposomes (LPS) conjugated with CDH11 neutralizing antibody (antiCDH11) to target cell surface CDH11 and loaded these LPS with a BCL-2 inhibitor, Navitoclax (NAVI), to induce apoptosis of CDH11 expressing fibroblasts. The developed LPS were evaluated for physicochemical characterization, stability, in vitro therapeutic efficacy using dermal fibroblasts, and in vivo therapeutic efficacy in bleomycin-induced skin fibrosis model in mice. The findings from in vitro and in vivo studies confirmed that selectivity of LPS was improved towards CDH11 expressing myofibroblasts, thereby improving therapeutic efficacy with no indication of adverse effects. Hence, this novel research work represents a versatile LPS strategy that exhibits promising potential for treating skin fibrosis.
Journal
|
CDH11 (Cadherin 11)
|
CDH1 expression
|
navitoclax (ABT 263) • bleomycin
4d
Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer. (PubMed, Mol Cancer Res)
Combinational targeting of kinesins (ispinesib) with cabazitaxel was more effective than single monotherapies in inducing cell death in resistant prostate tumors. Implications: Our findings are of translational significance in identifying kinesin as a novel target of cross-resistance, towards enhancing therapeutic vulnerability and improved clinical outcomes in patients with advanced prostate cancer.
Journal • Metastases
|
CDH1 (Cadherin 1) • SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • VIM (Vimentin) • KIFC1 (Kinesin Family Member C1)
|
CDH1 expression • VIM expression • CDH1 overexpression
|
cabazitaxel • ispinesib (SB-715992)
4d
Underlying anti-cancer mechanisms of histone deacetylase (HDAC) inhibitors in tamoxifen-resistant breast cancer cells. (PubMed, Iran J Basic Med Sci)
This study aimed to explore the underlying mechanisms of histone deacetylase (HDAC) inhibitor trichostatin A (TSA) to overcome resistance to tamoxifen in breast cancer cells...Finally, expression of vascular endothelial growth factor (VEGF), E-cadherin, Vimentin, phosphorylated phosphatidylinositol kinase (p-PI3k), phosphorylated protein kinase B (p-AKT), and phosphorylated mammalian target protein of rapamycin (p-mTOR) was evaluated by western blotting...However, HDAC inhibitor combined with PI3K inhibitor exerts more profound effects on the cancer cells as compared to HDAC inhibitor monotherapy. HDAC inhibitors inhibited the survival of breast cancer drug-resistant cells, invasion, migration, and angiogenesis by inhibiting the PI3k/Akt/mTOR signaling pathway.
Journal • Epigenetic controller
|
CDH1 (Cadherin 1) • VIM (Vimentin)
|
CDH1 expression • VEGFA expression
|
tamoxifen • sirolimus • trichostatin A (VTR-297)
4d
Melatonin inhibits tongue squamous cell carcinoma: Interplay of ER stress-induced apoptosis and autophagy with cell migration. (PubMed, Heliyon)
Moreover, MT inhibited tumor growth in nude mice inoculated with CRL-1623 cells. These results suggest that MT could induce autophagy, promote apoptosis, and provide a potential natural compound for the treatment of TSCC.
Journal
|
BAP1 (BRCA1 Associated Protein 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • BAX (BCL2-associated X protein) • WNT5A (Wnt Family Member 5A) • H19 (H19 Imprinted Maternally Expressed Transcript) • ATF4 (Activating Transcription Factor 4) • ATF6 (Activating Transcription Factor 6) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • BECN1 (Beclin 1) • CCNB1 (Cyclin B1)
|
CDH1 expression • BAX expression • ZEB1 expression
6d
Banxia Xiexin Decoction inhibiting colitis-associated colorectal cancer infected with Fusobacterium nucleatum by regulating Wnt/β-catenin pathway (PubMed, Zhongguo Zhong Yao Za Zhi)
The protein content of E-cadherin and GSK-3β increased, while that of Wnt3a, β-catenin, annexin A1, and cyclin D1 decreased. In conclusion, BXD can inhibit CAC infected with Fn, and its potential mechanism may be related to the inhibition of Fn binding to E-cadherin, the decrease in annexin A1 protein level, and the regulation of the Wnt/β-catenin pathway.
Journal
|
CCND1 (Cyclin D1) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • IL2 (Interleukin 2) • ANXA1 (Annexin A1) • IL4 (Interleukin 4)
|
CDH1 expression
6d
Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the European Lobular Breast Cancer Consortium. (PubMed, Mod Pathol)
The E-cadherin IHC staining pattern was associated with variant allele frequency and likelihood of non-sense mediated RNA decay but not with the type or position of CDH1 mutations. Based on these results, we make recommendations for the indication for E-cadherin staining, choice of antibodies, and their interpretation in order to standardize ILC diagnosis in current pathology practice.
Journal
|
CDH1 (Cadherin 1) • CDH3 (Cadherin 3)
|
CDH1 expression • CDH1 mutation
6d
RAC1-mediated Integrin alpha-6 expression in E-cadherin-deficient gastric cancer cells promotes interactions with the stroma and peritoneal dissemination. (PubMed, Cancer Lett)
These findings indicate that Cdh1 gene loss leads to abnormal expression and changes in the subcellular localization of ITGA6 through RAC1 signalling. The latter, through interactions with CAFs, allows for peritoneal dissemination.
Journal • Stroma
|
KRAS (KRAS proto-oncogene GTPase) • CDH1 (Cadherin 1) • RAC1 (Rac Family Small GTPase 1) • ITGA6 (Integrin, alpha 6)
|
KRAS G12 • CDH1 deletion • CDH1 expression • KRAS deletion
7d
Research on the anti-tumor effects of CRYAB in prostate cancer (PubMed, Zhonghua Nan Ke Xue)
CRYAB is down-regulated in PCa tissue and is associated with the anti- tumor function of PCa cells. It may affect the metastatic ability of prostate cancer cells by regulating epithelial-mesenchymal transition molecules. CRYAB mRNA has important diagnostic and prognostic value in PCa.
Journal
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • CRYAB (Crystallin Alpha B)
|
CDH1 expression
7d
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colon. (PubMed, J Pathol Clin Res)
The large bowel is a common metastatic site in ILC. In endoscopic colon biopsies, the typical noncohesive growth of ILC may be concealed by microenvironment-induced EPS and conversion to cohesive growth.
Journal • Metastases
|
CDH1 (Cadherin 1) • CDH3 (Cadherin 3)
|
CDH1 expression • CDH1 mutation
8d
Evaluation of Tumorigenic Properties of MDA-MB-231 Cancer Stem Cells Cocultured with Telocytes and Telocyte-Derived Mitochondria Following miR-146a Inhibition. (PubMed, DNA Cell Biol)
EMT (N-cadherin, vimentin, E-cadherin) and tumorigenic markers (BRCA1, P53, SOX2) of CSCs decreased after miR-146a inhibition. Bone marrow-derived telocytes and mitochondria derived from telocytes favored the reduction of CSC aggressiveness following this inhibition.
Journal • Cancer stem • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • CDH1 (Cadherin 1) • SOX2 • VIM (Vimentin) • CDH2 (Cadherin 2)
|
CDH1 expression • miR-146a expression
9d
Circ-10720 as a ceRNA adsorbs microRNA-1238 and modulates ZEB2 to boost NSCLC development by activating EMT. (PubMed, Eur J Med Res)
Circ-10720 acts as a ceRNA to adsorb miR-1238 and modulate ZEB2 to facilitate the proliferation, migration, invasion, and EMT of NSCLC cells.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)
|
CDH1 expression
10d
Cadherin-17 as a target for the immunoPET of adenocarcinoma. (PubMed, Eur J Nucl Med Mol Imaging)
Taken together, these data underscore that [89Zr]Zr-DFO-D2101 is a highly promising probe for the non-invasive visualization of CDH17 expression in PDAC. We contend that this radioimmunoconjugate could have a significant impact on the clinical management of patients with both PDAC and gastrointestinal adenocarcinoma, most likely as a theranostic imaging tool in support of CDH17-targeted therapies.
Journal
|
CDH17 (Cadherin 17)
|
CDH1 expression
11d
Congenital localized cutaneous Langerhans cell histiocytosis in a Holstein calf. (PubMed, J Vet Diagn Invest)
The masses were diagnosed as Langerhans cell histiocytosis. Congenital cutaneous Langerhans cell histiocytosis has not been reported previously in cattle, to our knowledge, and should be included in the differential diagnosis of congenital nodular skin lesions.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • ITGB2 (Integrin Subunit Beta 2) • MSR1 (Macrophage Scavenger Receptor 1)
|
CDH1 expression • VIM expression
12d
A study on the significance of serine hydroxymethyl transferase expression and its role in bladder cancer. (PubMed, Sci Rep)
It also influences the expression levels of E-cadherin and N-cadherin, ultimately impacting the malignant biological progression of bladder tumors. These results establish a correlation between SHMT2 and the malignant biological progression of BLCA, providing a theoretical basis for the early diagnosis and treatment of bladder cancer.
Journal
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • SHMT1 (Serine Hydroxymethyltransferase 1) • SHMT2 (Serine Hydroxymethyltransferase 2)
|
CDH1 expression
13d
Subcellular expression of MTA1, HIF1A and p53 in primary tumor predicts aggressive triple negative breast cancers: a meta-analysis based study. (PubMed, J Mol Histol)
Our study suggests cytoplasmic over expression of HIF1A, nuclear over expression of MTA1 and mutated p53 in the primary tumor tissue of TNBC have significance as markers predicting survival of TNBC patients.
Retrospective data • Journal
|
TP53 (Tumor protein P53) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CDH1 (Cadherin 1) • BIRC5 (Baculoviral IAP repeat containing 5) • VIM (Vimentin)
|
TP53 mutation • HIF1A overexpression • TP53 expression • BIRC5 expression • CDH1 expression • HIF1A expression
13d
Differential Competitive Growth of Transgenic Subclones of Neuroblastoma Cells Expressing Different Levels of Cathepsin D Co-Cultured in 2D and 3D in Response to EGF: Implications in Tumor Heterogeneity and Metastasis. (PubMed, Cancers (Basel))
The present findings support the view that during NB growth on a substrate or when spreading as floating neurospheres, CD expression is epigenetically modulated to confer survival advantage. Thus, epigenetic targeting of CD could represent an additional strategy to prevent NB metastases.
Journal
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • CTSD (Cathepsin D)
|
CDH1 expression
13d
Proteomics-derived biomarker panel facilitates distinguishing primary lung adenocarcinomas with intestinal or mucinous differentiation (PAIM) from lung metastatic colorectal cancer (lmCRC). (PubMed, Mol Cell Proteomics)
Our study depicts PAIM-specific proteomic characteristics and demonstrates the potential utility of new protein biomarkers for the differential diagnosis of PAIM and lmCRC. These findings may contribute to improving the diagnostic accuracy and guide appropriate treatments for these patients.
Journal • Metastases
|
MLPH (Melanophilin) • CDH17 (Cadherin 17) • FABP1 (Fatty Acid Binding Protein 1)
|
CDH1 expression
14d
Transcriptomics studies reveal functions of Transglutaminase 2 in breast cancer cells using membrane permeable and impermeable inhibitors. (PubMed, J Mol Biol)
To effectively utilize these molecules as an anti-tumor strategy, an appropriate delivery system should be evaluated to target specific functions and avoid adverse effects. Additionally, considering combinations with other pathway modulators is crucial.
Journal
|
TGM2 (Transglutaminase 2) • GAST (Gastrin 2)
|
CDH1 expression
15d
Arsenic and Benzo[a]pyrene Co-exposure Effects on MDA-MB-231 Cell Viability and Migration. (PubMed, Biol Trace Elem Res)
However, there were no observable changes in the expression of E-cadherin mRNA. Consequently, additional research is required to evaluate the prolonged effects of co-exposure to As and BaP on the initiation of EMT and the progression of breast cancer.
Journal
|
BAP1 (BRCA1 Associated Protein 1) • CDH1 (Cadherin 1) • VIM (Vimentin)
|
CDH1 expression • VIM expression
15d
A novel four‑gene biomarker for tobacco smoking -induced colorectal cancer progression. (PubMed, Nicotine Tob Res)
This study demonstrates tobacco-derived NNK dependence would promote the malignant progression of colorectal cancer through regulating the expressions of AKR1B10/Wnt signaling pathway. And a novel four-gene signature is established for the prognosis prediction of smoking CRC patients. These findings have important translational implications given the continued use of tobacco and the difficulty in smoking cessation worldwide, which can be applied to alleviate the adverse effects induced by tobacco dependence on colorectal cancer patients.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • AKR1B10 (Aldo-Keto Reductase Family 1 Member B10) • CALB2 (Calbindin 2)
|
CDH1 expression • VIM expression
15d
Lutein inhibits the adhesion, invasiveness and metastasis of human prostate cancer PC-3M cells (PubMed, Zhonghua Nan Ke Xue)
Lutein can inhibit cell adhesion, reduce the expressions of MMPs, and suppress cell invasion and migration by inhibiting the process of epithelial-mesenchymal transition.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • PXN (Paxillin)
|
CDH1 expression • VIM expression • TIMP1 expression
17d
MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4. (PubMed, World J Diabetes)
MiR-630 may inhibit the inflammatory reaction of DKD by targeting TLR4, and has a protective effect on DKD.
Preclinical • Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta) • MIR630 (MicroRNA 630)
|
CDH1 expression • IL6 expression
17d
METTL3-mediated m6A methylation of DNMT1 promotes the progression of non-small cell lung cancer by regulating the DNA methylation of FOXO3a. (PubMed, Heliyon)
DNMT1 knockdown upregulated the expression of FOXO3a and E-cadherin, while downregulated N-cadherin expression in vivo. METTL3-mediated m6A methylation of DNMT1 up-regulates FOXO3a promoter methylation, thereby promoting the progression of NSCLC.
Journal • Epigenetic controller
|
CDH1 (Cadherin 1) • DNMT1 (DNA methyltransferase 1) • CDH2 (Cadherin 2) • FOXO3 (Forkhead box O3) • METTL3 (Methyltransferase Like 3)
|
CDH1 expression • DNMT1 overexpression
18d
Wortmannin Inhibits Cell Growth and Induces Apoptosis in Colorectal Cancer Cells by Suppressing the PI3K/AKT Pathway. (PubMed, Anticancer Agents Med Chem)
This study underscores Wortmannin's potential in inhibiting CRC cell growth and migration through PI3K/Akt pathway modulation. It also highlights its candidacy for further investigation as a promising therapeutic option in colorectal cancer treatment.
Journal
|
CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • BIRC5 (Baculoviral IAP repeat containing 5) • ANXA5 (Annexin A5)
|
CDH1 expression
|
5-fluorouracil
18d
Genomic and Pathologic Profiling of Very Well-Differentiated Gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation. (PubMed, Am J Surg Pathol)
This study demonstrated that a subset of RHOA-mutant diffuse-type gastric cancers develops through the transformation of very well-differentiated adenocarcinoma of intestinal type. Our observations suggest a mixed mucin phenotype as a risk factor and alterations in p53 and E-cadherin as drivers of diffuse-type transformation.
Journal
|
TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • CLDN18 (Claudin 18) • CDH1 (Cadherin 1) • RHOA (Ras homolog family member A)
|
TP53 mutation • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • TP53 expression • CDH1 expression
18d
Diagnostic Pitfall of Gastric Signet-Ring Cells: How to Diagnose a Benign Signet-Ring Cell From a Malignant One. (PubMed, Int J Surg Pathol)
In contrast, cells in signet-ring cell adenocarcinoma strongly express p53, have high proliferation rates, and show either no or weak E-cadherin staining. Genetic analysis may be useful in identifying patients at risk of hereditary early diffuse gastric adenocarcinoma, which can mimic signet-ring cell change.
Journal
|
TP53 (Tumor protein P53) • CDH1 (Cadherin 1)
|
TP53 wild-type • TP53 expression • CDH1 expression
20d
Degradation of FAK-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma. (PubMed, Oncol Res)
Increased expression of E-cadherin and decreased expression of vimentin indicated that EMT was inhibited. Consequently, degradation of FAK through FAK PROTAC effectively suppressed liver cancer metastasis, holding significant clinical implications for treating liver cancer and developing innovative anti-neoplastic drugs.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • PTK2 (Protein Tyrosine Kinase 2)
|
CDH1 expression • VIM expression
21d
MiR-383-5p inhibits the proliferation and migration of lung adenocarcinoma cells by targeting SHMT2. (PubMed, J Cancer)
Exogenous overexpression of SHMT2 reversed the miR-383-5p-induced proliferation and migration inhibition in A549 and H1299 cells. MiR-383-5p inhibits the proliferation and migration of lung adenocarcinoma cells by targeting and downregulating SHMT2.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • MIR383 (MicroRNA 383) • SHMT2 (Serine Hydroxymethyltransferase 2)
|
CCND1 expression • CDH1 expression • VIM expression
22d
Matrine Enhances the Antitumor Efficacy of Chidamide in CTCL by Promoting Apoptosis. (PubMed, Recent Pat Anticancer Drug Discov)
Our data have demonstrated chidamide combined with matrine to exhibit elevated antitumor activity in both CTCL cells and xenograft models of NOD/SCID mice, which may be a potential treatment option for CTCL.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1)
|
CDH1 expression
|
Epidaza (chidamide)
23d
Suppression of JAK2/STAT3 Pathway by Notoginsenoside R1 Reduces Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer. (PubMed, Mol Biotechnol)
Moreover, a specific inhibitor of JAK2, AG490, or STAT3 silencing significantly enhanced the effects of NGR1 against the EMT process in NSCLC cells. NGR1 restrains EMT process in NSCLC by inactivating JAK2/STAT3 signaling, suggesting the potential of NGR1 in anti-NSCLC therapy.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • SNAI1 (Snail Family Transcriptional Repressor 1)
|
CDH1 expression • VIM expression
24d
Prognostic significance of E-Cadherin and B-Catenin in non-muscle invasive bladder cancer. (PubMed, J Immunoassay Immunochem)
05), grade (p = 0.02), and recurrence (p = 0.02). The abnormal expression of these markers could help to identify a high-risk subgroup of NMIBC that might benefit from either more accurate follow-up or more aggressive treatment.
Journal
|
CDH1 (Cadherin 1)
|
CDH1 expression
25d
A novel imprinted locus on bovine chromosome 18 homologous with human chromosome 16q24.1. (PubMed, Mol Genet Genomics)
Two DMRs were located between the ZDHHC7 and KIAA0513 genes, and two were in exon 1 of the CDH13 and ATP2C2 genes, respectively. The results from this study support future studies on the molecular mechanism to regulate the imprinting of candidate genes on bovine chromosome 18.
Journal
|
GSE1 (Gse1 Coiled-Coil Protein)
|
CDH1 expression
25d
Expression of E-Cadherin and N-Cadherin in the Endocervix as a Predictive Factor in Patients with Endometrial Cancer. (PubMed, Int J Mol Sci)
E-cadherin and N-cadherin were expressed in the endocervix in patients with EC. The expression of cadherins, determined during cervical cytology, may be a valuable clinical marker of EC.
Retrospective data • Journal
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2)
|
CDH1 expression
25d
Tetrastigma hemsleyanum (Sanyeqing) root extracts evoke S phase arrest while inhibiting the migration and invasion of human pancreatic cancer PANC-1 cells. (PubMed, BMC Complement Med Ther)
Treatment of PANC-1 with EFT demonstrated measurable cytotoxic effects. Furthermore, EFT evoked S phase arrest while inhibiting the migration and invasion of PANC-1 cells. Additionally, EFT inhibited the epithelial to mesenchymal transition and MMPs expression in PANC-1 cells. This study serves to confirm the strong therapeutic potential of EFT while identifying the mechanisms of action.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • FN1 (Fibronectin 1) • VIM (Vimentin) • CDK2 (Cyclin-dependent kinase 2) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
CDH1 expression • VIM expression
25d
METTL3 Promotes Osteosarcoma Metastasis via an m6A-dependent Epigenetic Activity of CBX4. (PubMed, Front Biosci (Landmark Ed))
These results suggest that the combined action of METTL3 and CBX4 plays an important role in the regulation of metastasis of osteosarcoma, and therefore, the METTL3-CBX4 axis pathway may be a new potential therapeutic target for osteosarcoma.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • METTL3 (Methyltransferase Like 3)
|
CDH1 expression
26d
Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial-Mesenchymal Transition Metastatic Phenotype. (PubMed, Cells)
This approach was further substantiated by findings that the neuromedin B receptor inhibitor, BIM-23127, MMP-9 inhibitor, MMP9i, and Neu-1 inhibitor, oseltamivir phosphate, could specifically block CB1 agonist-induced Neu-1 sialidase activity...Moreover, the study results demonstrate that CB1 agonists induce NFκB-dependent secretory alkaline phosphatase (SEAP) activity in influencing the expression of epithelial-mesenchymal markers, E-cadherin, and vimentin in SW-620 cells, albeit the impact on E-cadherin expression is less pronounced compared to vimentin. In essence, this innovative research begins to elucidate an entirely new molecular mechanism involving a GPCR signaling paradigm in which cannabinoids, as epigenetic stimuli, may traverse to influence gene expression and contribute to cancer and cancer metastasis.
Journal • Metastases
|
CDH1 (Cadherin 1) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
|
CDH1 expression • VIM expression
26d
Tumoricidal properties of thymoquinone on human colorectal adenocarcinoma cells via the modulation of autophagy. (PubMed, BMC Complement Med Ther)
Here, we monitored the effects of Thymoquinone (TQ) on autophagy via mitochondrial function after modulation of the Wnt/β-catenin signaling pathway.Human colorectal adenocarcinoma HT-29 cells were treated with TQ (60 µM) and 15 µM Wnt3a inhibitor (LGK974) for 48 h...TQ can increase intracellular accumulation of Rhodamine 123, indicating the inhibition of efflux mechanisms in cancer cells. Along with these changes, the migration of cells was also reduced (p < 0.05).TQ is a potential phytocompound to alter the dynamic growth of human colorectal HT-29 cells via the modulation of autophagy, and mitophagy-related mechanisms.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AXIN1 (Axin 1) • BECN1 (Beclin 1) • CDH5 (Cadherin 5) • PINK1 (PTEN Induced Kinase 1)
|
MYC expression • CDH1 expression
|
WNT974
27d
Wogonin inhibits the migration and invasion of fibroblast-like synoviocytes by targeting PI3K/AKT/NF-κB pathway in rheumatoid arthritis. (PubMed, Arch Biochem Biophys)
Wogonin effectively inhibits migration, invasion and pro-inflammatory cytokine production of RA fibroblast-like synoviocytes through the PI3K/AKT/NF-κB pathway, and thus wogonin, as a natural flavonoid, has great potential for treating RA.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • IL10 (Interleukin 10) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • MMP3 (Matrix metallopeptidase 3)
|
CDH1 expression